51802-42-7

Usage

Uses

Used in Pharmaceutical Industry:
2-PROPYL-1H-IMIDAZOLE-4,5-DICARBONITRILE is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of diverse molecular entities with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-PROPYL-1H-IMIDAZOLE-4,5-DICARBONITRILE is employed as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds, thereby improving crop yields and quality.
Used in Organic Chemistry Research:
2-PROPYL-1H-IMIDAZOLE-4,5-DICARBONITRILE is used as a ligand in coordination chemistry, enabling the formation of coordination complexes with metal ions. This application is crucial for studying the properties and reactivity of metal complexes, which can further our understanding of their potential uses in catalysis, materials science, and other areas.
Used in Fine Chemicals Production:
As an intermediate in the production of fine chemicals, 2-PROPYL-1H-IMIDAZOLE-4,5-DICARBONITRILE plays a vital role in the synthesis of specialty chemicals used in various industries, such as fragrances, dyes, and advanced materials. Its presence in these compounds can impart unique properties and functionalities, expanding their applications and market potential.

InChI:InChI=1/C8H8N4/c1-2-3-8-11-6(4-9)7(5-10)12-8/h2-3H2,1H3,(H,11,12)

Upstream product

• 43083-12-1 1,1,1-trimethoxybutane 
• 1187-42-4 diaminomaleonitrile 
• 18514-52-8 2,3-diaminomaleonitrile 
• 761441-46-7 N-((Z)-2-amino-1,2-dicyanoethenyl)butyramide 

Downstream Products

• 58954-23-7 2-propyl-1H-imidazole-4,5-dicarboxylic acid 
• 144689-96-3 2-propyl-1-tritylimidazole-4,5-dicarbonitrile 
• 144689-85-0 2-butyl-1-tritylimidazole-4,5-dicarbonitrile 
• 1020157-01-0 (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(2-triphenylmethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl-1H-imidazole-5-carboxylate 
• 1027174-22-6 5-(1-Hydroxy-1-methyl-ethyl)-2-propyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester 
• 172875-56-8 2-Propyl-1-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-imidazole-4,5-dicarboxylic acid diethyl ester 
• 172876-04-9 5-Hydroxymethyl-2-propyl-1-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-imidazole-4-carboxylic acid ethyl ester 
• 172875-70-6 5-Isopropenyl-2-propyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 172875-59-1 ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl-1H-imidazole-5-carboxylate 
• 172875-72-8 5-(1-Hydroxy-ethyl)-2-propyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 172876-01-6 5-Hydroxymethyl-2-propyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 172875-61-5 5-Isopropyl-2-propyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 172875-69-3 2-Propyl-1-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-imidazole-4-carboxylic acid ethyl ester 
• 144689-63-4 olmesartan medoxomil 

Relevant academic research and scientific papers

Preparation method of diacid

The invention relates to a preparation method of diacid, and belongs to the field of medicinal chemistry. The preparation method provided by the invention comprises: carrying out carboxylation reaction on raw materials under the action of acid under a continuous flow reaction condition. The method provided by the invention has the advantages of cheap and easily available raw materials, simple process, low cost, high product purity and yield, green and environment-friendly process, and facilitation of industrialization.

Efficient synthesis of olmesartan medoxomil, an antihypertensive drug

This document describes a simple and robust process for the synthesis of olmesartan medoxomil. This tailored process allows us to synthesize olmesartan medoxomil on a large scale with 50% overall yield. Also, our process has excellent control of the impurity profile in all the stages. Copyright Taylor & Francis Group, LLC.

Efficient synthesis of trisimidazole and glutaric acid bearing porphyrins: Ligands for active-site models of bacterial nitric oxide reductase

Ligands (1) for active-site models of bacterial nitric oxide reductase (NOR) have been efficiently synthesized. These compounds (1) feature three imidazolyl moieties and one carboxylic acid residue at the FeB site, which represent the closest available synthetic model ligands of NOR active center. The stereo conformations of these ligands are established on the basis of steric effects and 1H NMR chemical shifts under the ring current effect of the porphyrin.

Synthesis of 4,5-dicyanoimidazoles

The effective procedure of preparation of 2-trifluoromethyl-4,5- dicyanoimidazole (3a) from diaminomaleonitrile (1) and trifluoroacetic anhydride has been elaborated. The syntheses of five other 2-substituted imidazoles from appropriate acyl derivatives of 1 have been attempted. Out of them only 4,5-dicyanoimidazole (3b) could be obtained in good yield.

ANGIOTENSIN II ANTAGONIST 1-BIPHENYLMETHYLIMIDAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE

Compounds of the following formula (I) or the formula (I) p : STR1 wherein R 1 is alkyl or alkenyl; R 2 and R 3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R 4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula--SiR a R b R c, in which R a, R b and R c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R 5 is carboxy or--CONR 8 R 9, wherein R 8 and R 9 hydrogens or alkyl, or R 8 and R 9 together form alkylene; R 6 is hydrogen, alkyl, alkoxy or halogen; R. sup.7 is carboxy or tetrazol-5-yl; R p. sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R p 2 is a single bond, alkylene or alkylidene; R p 3 and R p 4 are each hydrogen or alkyl; R. sub.p 6 is carboxy or tetrazol-5-yl; and X p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.

Nonpeptide angiotensin II receptor antagonists: Synthesis, biological activities, and structure - Activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds

A series of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds were prepared and evaluated for their antagonistic activities to the angiotensin II (AII) receptor. Among them, the 4-(1-hydroxyalkyl)-imidazole derivatives had strong binding affinity to the AII receptor and potently inhibited the AII-induced pressor response by intravenous administration. Various esters of these acids showed potent and long-lasting antagonistic activity by oral administration. The most promising compounds were (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (CS-866) and (pivaloyloxy)-methyl esters of 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[(2′-1H-tetrazol-5-ylbiphenyl-4-yl) -methyl]imidazole-5-carboxylic acid (26c). A study involving stereochemical comparison of 26c with the acetylated C-terminal pentapeptide of AII was also undertaken.